Is Therapy-Induced HBs Decline the Same as Naturally Low HBs? - Jordan Feld

International Workshop on HBV Cure 2022

Bulevirtide - Data from Real World Usage after Approval in Europe - John Flaherty

International Workshop on HBV Cure 2022

Why We Should Be Careful Using NA Withdrawal as a Therapeutic Option - Pietro Lampertico

International Workshop on HBV Cure 2022

HBV-Specific T Cell Profile Associated with Functional Cure - Georg Lauer

International Workshop on HBV Cure 2022

How HBV RNA and HBcrAg Relate to cccDNA Transcriptional Activity - Barbara Testoni

International Workshop on HBV Cure 2022

Evidence of T Cell Restoration after siRNA Therapy - Emily Thi

International Workshop on HBV Cure 2022

Development of Assembly Next Generation Core Inhibitors - Grace Wang

International Workshop on HBV Cure 2022

Therapy Induced Flares Associated With HBsAg Decline - Man-Fung Yuen

International Workshop on HBV Cure 2022

Short Talk: Cabotegravir/Rilpivirine Failures Despite Adherence - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Short Talk: Islatravir Toxicity - Charles Flexner, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Point of Care Tests for Drug Level Testing: Where Are We? - Paul K. Drain, MD, MPH, FIDSA

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Strategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals - Adeniyi Olagunju, BPharm, MRes, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Multipurpose Prevention Technologies (MPTs) For Prevention of HIV and Pregnancy - Sharon L. Hillier, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacokinetics of mAbs in Prevention, Treatment and Cure of Viral Infections -Edmund Capparelli, PharmD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Optimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals -Angela Colbers, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacology Pearls for Managing Absorption and Swallowing Difficulties - Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Age-Related Changes in Pharmacokinetics and Pharmacodynamics - Catia Marzolini, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

The Non-adherent Patient: A Good or Bad Candidate for CAB+RPV? - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir for Treatment and Prevention - M. Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir for Treatment and Prevention: When Are You Protected? - M. Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

What’s on the Horizon for Direct Acting Antivirals for Hepatitis B? - Jennifer Kiser, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Recent Developments in Antivirals Against Herpes Simplex Virus Infection - Scott H. James, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacology Considerations of Future ART/PrEP Regimens - Marta Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Session 2: Discussion with the Audience | International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022